US20210364506A1 - Methods for detecting an amount of an analyte in a solution - Google Patents
Methods for detecting an amount of an analyte in a solution Download PDFInfo
- Publication number
- US20210364506A1 US20210364506A1 US16/881,489 US202016881489A US2021364506A1 US 20210364506 A1 US20210364506 A1 US 20210364506A1 US 202016881489 A US202016881489 A US 202016881489A US 2021364506 A1 US2021364506 A1 US 2021364506A1
- Authority
- US
- United States
- Prior art keywords
- solution
- value
- analyte
- signal
- active agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012491 analyte Substances 0.000 title claims abstract description 118
- 238000000034 method Methods 0.000 title claims abstract description 86
- 239000000523 sample Substances 0.000 claims abstract description 67
- 230000011664 signaling Effects 0.000 claims abstract description 57
- 239000013543 active substance Substances 0.000 claims abstract description 47
- 230000008859 change Effects 0.000 claims abstract description 26
- 238000006479 redox reaction Methods 0.000 claims abstract description 21
- 230000027455 binding Effects 0.000 claims description 48
- 238000009739 binding Methods 0.000 claims description 48
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 45
- 229940079593 drug Drugs 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 39
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 26
- 239000000975 dye Substances 0.000 claims description 13
- -1 hydrogen (H+) ions Chemical class 0.000 claims description 11
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 8
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims description 8
- 239000007850 fluorescent dye Substances 0.000 claims description 7
- 238000009396 hybridization Methods 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 238000001179 sorption measurement Methods 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108091006047 fluorescent proteins Proteins 0.000 claims description 5
- 102000034287 fluorescent proteins Human genes 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 claims description 4
- 229930192627 Naphthoquinone Natural products 0.000 claims description 4
- 150000002791 naphthoquinones Chemical class 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 139
- 238000003556 assay Methods 0.000 description 71
- 238000010586 diagram Methods 0.000 description 16
- 239000012488 sample solution Substances 0.000 description 16
- 230000001419 dependent effect Effects 0.000 description 14
- 238000003018 immunoassay Methods 0.000 description 13
- 238000007254 oxidation reaction Methods 0.000 description 13
- 238000001514 detection method Methods 0.000 description 11
- 239000003596 drug target Substances 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- 238000006722 reduction reaction Methods 0.000 description 9
- 238000012286 ELISA Assay Methods 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 7
- 238000002203 pretreatment Methods 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 238000010306 acid treatment Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 5
- 229940126587 biotherapeutics Drugs 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 102000003816 Interleukin-13 Human genes 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102100034608 Angiopoietin-2 Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- XARHBOJGLNWMPG-UHFFFAOYSA-N 1-phenyl-2-(trifluoromethyl)diaziridine Chemical compound FC(F)(F)N1N(C1)C1=CC=CC=C1 XARHBOJGLNWMPG-UHFFFAOYSA-N 0.000 description 1
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- ACNUVXZPCIABEX-UHFFFAOYSA-N 3',6'-diaminospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(N)C=C1OC1=CC(N)=CC=C21 ACNUVXZPCIABEX-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- 239000004713 Cyclic olefin copolymer Substances 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 108010082025 cyan fluorescent protein Proteins 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000005401 electroluminescence Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910021644 lanthanide ion Inorganic materials 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012910 preclinical development Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical class [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- DYPYMMHZGRPOCK-UHFFFAOYSA-N seminaphtharhodafluor Chemical compound O1C(=O)C2=CC=CC=C2C21C(C=CC=1C3=CC=C(O)C=1)=C3OC1=CC(N)=CC=C21 DYPYMMHZGRPOCK-UHFFFAOYSA-N 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000001018 xanthene dye Substances 0.000 description 1
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3275—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction
- G01N27/3277—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction being a redox reaction, e.g. detection by cyclic voltammetry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
- G01N33/5438—Electrodes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
Definitions
- the present disclosure relates to methods for detecting an amount of an analyte in a solution, for example, methods for detecting an amount of an analyte in an immunoassay.
- Suboptimal performance of protein assays is often due to sample complexity and non-specific interactions, especially for some immunogenicity assays and cytokine assays.
- drugs can bind to anti-drug antibodies (ADA), thereby forming drug-ADA complexes which can adversely affect an accurate quantification of the concentration of the ADA or the drug.
- cytokines and protein biomarkers often have native binding partners in blood and serum, and complexes can also be formed in an assay to affect an accurate detection of a target analyte.
- a pH treatment step can be performed to break up such complexes and other undesired interactions prior to assaying a sample. However, this step is often performed manually, which is not ideal for accurately measuring the concentration of a target analyte in the sample.
- a method for detecting an amount of an analyte in a solution may include adding an electrochemically active agent to the solution containing molecules other than the electrochemically active agent.
- the electrochemically active agent can generate or consume hydrogen (H + ) ions in the solution through an electrochemical redox reaction.
- the method may also include applying an electrical current to a working electrode in contact with the solution containing the electrochemically active agent to initiate the electrochemical redox reaction to change a pH of the solution from a first pH value to a second pH value, where the second pH value may be different from the first pH value.
- the method may further include incubating the solution at the second pH value to allow the analyte to dissociate from the other molecules in the solution, where the incubating step may further include incubating the solution at the second pH value to allow the analyte to bind to a capture molecule connected to the working electrode via a linker.
- the method may also include reacting a detecting probe with the analyte to allow the detecting probe to bind to the analyte.
- the detecting probe may have a signaling tag attached thereto and configured to produce a signal at the second pH value.
- the method may further include collecting the signal to calculate the amount of the analyte in the solution.
- a method for detecting an amount of an analyte in a solution may include adding an electrochemically active agent to the solution containing molecules other than the electrochemically active agent.
- the electrochemically active agent can generate or consume hydrogen (H + ) ions in the solution through an electrochemical redox reaction.
- the method may also include applying a first electrical current to a working electrode in contact with the solution containing the electrochemically active agent to initiate a first electrochemical redox reaction to change a pH of the solution from a first pH value to a second pH value, where the second pH value may be different from the first pH value.
- the method may further include incubating the solution at the second pH value to allow the analyte to dissociate from the other molecules in the solution.
- the method may also include applying a second electrical current to the working electrode to initiate a second electrochemical redox reaction to change the pH of the solution from the second pH value to a third pH value, where the third pH value may be different from the second pH value.
- the method may further include incubating the solution at the third pH value to allow the analyte to bind to a capture molecule connected to the working electrode via a linker.
- the method may also include reacting a detecting probe with the analyte to allow the detecting probe to bind to the analyte.
- the detecting probe may have a signaling tag attached thereto and configured to produce a signal at the third pH value.
- the method may further include collecting the signal to calculate the amount of the analyte in the solution.
- a method for detecting an amount of an analyte in a solution with a first pH value may include adding a detecting probe to the solution.
- the detecting probe may have a signaling tag attached thereto and configured not to produce a signal at the first pH value.
- the method may also include adding an electrochemically active agent to the solution containing molecules other than the electrochemically active agent and the detecting probe.
- the electrochemically active agent can generate or consume hydrogen (H + ) ions in the solution through an electrochemical redox reaction.
- the method may further include applying a first electrical current to a working electrode in contact with the solution to initiate a first redox reaction to change a pH of the solution from the first pH value to a second pH value, where the second pH value may be different from the first pH value.
- the method may also include incubating the solution at the second pH value to allow the analyte to dissociate from the other molecules in the solution and to bind to a capture molecule connected to the working electrode via a linker and to the detecting probe.
- the signaling tag attached to the detecting probe may be configured to produce a first signal at the second pH value.
- the method may further include collecting the first signal to calculate a first amount of the analyte in the solution.
- the method may also include applying a second electrical current to the working electrode in contact with the solution to initiate a second redox reaction to change the pH of the solution from the second pH value to a third pH value, where the third pH value may be different from the second pH value.
- the method may further include incubating the solution at the third pH value, where the signaling tag may be configured to produce a second signal at the third pH value.
- the second signal may be stronger than the first signal.
- the method may also include collecting the second signal to calculate a second amount of the analyte in the solution, where the second amount may be higher than the first amount.
- FIG. 1 depicts a schematic diagram of a method for detecting an amount of an analyte in an assay.
- FIG. 2 depicts a schematic diagram illustrating an interference of the presence of soluble binding partners of an analyte with the detection of an amount of the analyte in an assay.
- FIG. 3 depicts a schematic diagram illustrating an acid pre-treatment step to dissociate analytes from soluble binding partners of the analytes in an assay.
- FIG. 4 depicts a schematic diagram illustrating a first method embodiment for detecting an amount of an analyte in an assay.
- FIG. 5 depicts a schematic diagram illustrating a second method embodiment for detecting an amount of an analyte in an assay.
- FIG. 6 depicts a schematic diagram illustrating a third method embodiment for detecting an amount of an analyte in an assay.
- FIG. 7 depicts a schematic diagram illustrating a fourth method embodiment for detecting an amount of an analyte in an assay.
- FIG. 8 depicts a schematic diagram illustrating a fifth method embodiment for detecting an amount of an analyte in an assay.
- Biotherapeutics such as proteins and monoclonal antibodies (mAbs)
- mAbs monoclonal antibodies
- Biotherapeutics are growing fast on the pharmaceutical market.
- Biotherapeutics compared to relatively small molecule drugs, are prone to the risk of immune responses.
- an unwanted immunogenicity may lead to a production of anti-drug antibodies (ADAs), which can negatively impact drug levels in circulation and drug efficacy.
- ADAs anti-drug antibodies
- immune responses can be severe and life threatening. Therefore, to assess the risk of immune responses against biotherapeutics, pharmacokinetics (PK) and pharmacodynamics (PD) characterizations are necessary during pre-clinical development stages and clinical trials.
- PK pharmacokinetics
- PD pharmacodynamics
- PK and/or PD profiles for a biotherapeutic, it is important to accurately measure the concentration of ADAs, drugs, or both in an aqueous environment.
- high drug levels in the aqueous environment can adversely interfere with the detection of ADAs, especially in bridging assay formats.
- ADAs can form complexes with drugs in a sample solution, thereby preventing an accurate quantification of the concentration of the ADAs, the drugs, or both.
- Such an issue may be more common in multiple-dose studies, where drug concentrations remain high for a significant period of the studies.
- the drug-tolerant assays can measure the concentration of ADAs in the presence of drugs by adopting an acid treatment step.
- the acid treatment step can break up ADA-drug complexes and release ADAs and drugs to a sample solution.
- Some examples of the drug-tolerant assays include enzyme-linked immunosorbent assay (ELISA), affinity capture elution ELISA (ACE), biotin-drug extraction with acid dissociation (BEAD) assay, sample pretreatment bridging ELISA, acid dissociation radioimmunoassay, homogeneous mobility shift assay (HMSA), and precipitation and acid dissociation method.
- soluble drug targets may also present a challenge for immunoassays.
- the ratio of drugs to drug targets is low, very few binding sites of the drugs are available to engage the drug targets that are immobilized in an immunoassay.
- a reverse effect may be observed (i.e. very few binding sites of the drug targets are available to bind the drugs). Therefore, different ratios of drugs to drug targets in an immunoassay may also have an impact on the accuracy of measuring the PK and/or PD profiles for a biotherapeutic.
- an acid treatment step has been employed in performing an immunoassay.
- the acid treatment step may be conducted by modulating a pH of a sample solution, thereby dissociating drugs from drug targets and denaturing drug-binding epitopes on drug targets.
- the sample solution may then be neutralized and ready for analysis in an ELISA format.
- This method has been used for the detection of immunoglobulin G1 (IgG1) mAb in the presence of angiopoietin-2 (Ang2).
- a sample may be subject to a mild acid treatment, followed by a direct analysis on the sample using a sandwich ELISA.
- This method does not denature drug-binding epitopes on drug targets, but it utilizes the ability of capture antibodies to bind to drugs at a specific pH value where the drugs and the drug targets remain dissociated (i.e. drugs are unbound to drug targets).
- This method has been applied to the detection of immunoglobulin G4 (IgG4) in the presence of a soluble circulating target.
- an improved assay conducted in an acidic pH value has been utilized for the detection of interleukin 13 (IL-13) in human plasma and serum.
- incubation of a sample at the acidic pH value can reduce non-specific binding and interference from IL-13 binding proteins.
- biomarkers known to have soluble binding partners in blood and serum are, but not limited to, interleukin 1 (IL-1), interleukin 18 (IL-18), insulin-like growth factor 1 (IGF-1), tumor necrosis factor-beta (TNF- ⁇ ), and testosterone.
- a sample solution may be diluted in acetic acid and then incubated for 1 hour. Thereafter, the solution may be mixed with a basic buffer (e.g. Tris pH 9.5) and then added to an assay plate which contains a surface-bound capture molecule (e.g. antigen). The solution may then be incubated for another 1 to 5 hours, followed by washing and signal amplification steps (e.g. using horseradish peroxidase, or alkaline phosphatase).
- a basic buffer e.g. Tris pH 9.5
- an assay plate which contains a surface-bound capture molecule (e.g. antigen).
- the solution may then be incubated for another 1 to 5 hours, followed by washing and signal amplification steps (e.g. using horseradish peroxidase, or alkaline phosphatase).
- the acid treatment step introduced in each method is performed manually. Manual operations can unavoidably introduce human errors, causing a low reproducibility of an assay. Therefore, there is a need to detect an amount of an analyte, such as an ADA, in an immunoassay in a more efficient and accurate manner.
- an analyte such as an ADA
- the pH of the sample solution may be modulated automatically.
- Methods of electrochemically modulating a pH of a sample solution, especially varying the pH of the sample solution near an electrode surface have been disclosed in U.S. patent application Ser. Nos. 14/792,569 and 13/543,300, which are hereby incorporated by reference in their entirety.
- modulating pH electrochemically can give advantages toward performing an assay, including reducing the number of manual steps and reagents, shortening assay times, allowing multiplexing, and improving measurement accuracy.
- a system for electrochemically modulating a pH of a sample solution may include a working electrode and a counter electrode.
- the system may also include an electrochemically active agent, such as quinone, which may be added to the sample solution.
- the electrochemically active agent may undergo an electrochemical redox reaction (i.e. oxidation or reduction) under the influence of an electrical current.
- the electrochemical redox reaction of the electrochemically active agent may generate or consume hydrogen (H + ) ions, causing a pH change in the sample solution.
- H + hydrogen
- the system may also include a reference electrode and a sensing electrode. The sensing electrode may actively measure the pH of the sample solution in real time.
- Signals generated from the sensing electrode may be transmitted to electronics and fed into a closed loop algorithm, which may be used to control the electrical current applied to the working electrode and configured to either change or maintain the pH in the sample solution.
- a closed loop algorithm which may be used to control the electrical current applied to the working electrode and configured to either change or maintain the pH in the sample solution.
- Such an automatic method of pH modulation may be applied to analyzing immunoassays and other bioassays which may involve biomarkers that have soluble binding partners.
- the solution may include soluble binding partners of the analyte, which may bind to analytes in the solution to form complexes.
- the soluble binding partners may be drugs in the solution.
- the solution may also include detecting probes configured to bind to the analytes in the solution for detecting the amount of the analyte in the solution.
- Each detecting probe may include a signaling tag attached thereto.
- aspects of the present disclosure include an acid pre-treatment step where analytes, such as anti-drug antibodies (ADAs), may be dissociated from their binding partners, followed by binding to capture molecules and to detecting probes for detecting an amount of an analyte in a solution.
- analytes such as anti-drug antibodies (ADAs)
- aspects of the present disclosure include an acid pre-treatment step where analytes, such as ADAs, may be dissociated from their binding partners, followed by electrochemically modulating (e.g. neutralizing) a pH of a solution to allow the analytes to bind to capture molecules and to detecting probes for detecting an amount of an analyte in the solution.
- aspects of the present disclosure utilize detecting probes having pH-dependent signaling tags attached thereto for detecting an amount of an analyte, such as an ADA, in a solution, where a pH-dependent signaling tag may produce a first signal when the solution is at a first pH value, and may produce a second signal when the solution is at a second pH value different from the first pH value.
- an analyte such as an ADA
- FIG. 1 depicts a schematic diagram of a method for detecting an amount of an analyte in an assay.
- the assay may be a bridging ELISA assay.
- the analyte may be an ADA.
- a capture molecule 10 is attached to a solid substrate 12 (e.g. an electrode) via a linker 14 .
- An analyte 16 may bind to the capture molecule 10 .
- a detecting probe 18 may be present in the assay and may include a signaling tag 20 attached thereto. As illustrated in FIG. 1 , the detecting probe 18 may bind to the analyte 16 , and the signaling tag 20 may produce a signal. Thereafter, the amount of the analyte 16 in the assay may be calculated based on the signal.
- the linker 14 is configured to immobilize the capture molecule 10 and to preserve the functionality thereof.
- the linker 14 may be a polymeric material configured to immobilize the capture molecule through adsorption.
- the polymeric material may be, but not limited to, polystyrene, polymethyl methacrylate (PMMA), polypropylene, cyclic olefin copolymer, agarose, dextran, or nitrocellulose.
- the linker may also be a peptide sequence or a protein configured to immobilize the capture molecule through affinity.
- the peptide sequence or the protein may be, but not limited to, streptavidin, protein A, or protein G, an aptamer, or a polyhistidine tag (His-Tag).
- the linker may be a polynucleic acid configured to immobilize the capture molecule through hybridization.
- the linker may be an organic molecule for immobilizing the capture molecule through covalent bonding.
- the organic molecule may be, but not limited to, maleimide, succinimide, (trifluoromethyl)phenyldiaziridine, amine, hydrazide, boronic acid, iodoacetyl, epoxide, thiol, azide, or alkyne.
- the signaling tag 20 may be pH-dependent or pH-independent. Basically, a pH-dependent signaling tag may change its behavior as a function of a pH of a solution. For example, a pH-dependent signaling tag may produce a first signal at a first pH value and may produce a second signal at a second pH value, where the first and the second pH value are different. On the contrary, a pH-independent signaling tag may not change its behavior as a function of a pH of a solution, but rather produce a signal when it presents in a solution.
- the signaling tag 20 may be a fluorescent tag, a fluorescent dye, a fluorescent protein, an electroluminescent dye, a chemiluminescent dye, or an enzyme.
- fluorescent tags can be pH-dependent or pH-independent, which may be, but not limited to, organic dyes, quantum dots, lanthanide ions, or proteins.
- Fluorescent dyes may be, but not limited to, fluorescein, coumarin, rhodamin, cyanine, or derivatives thereof. Examples of commonly used fluorescent dyes include fluorescein isothiocyanate (FITC), tetramethylrhodamine isothiocyanate (TRITC), Alexa Fluor, Cy-3, Cy-5, and ATTO dyes.
- pH-dependent fluorescent dyes may include, but not limited to, pHrodo, Protonex, Oregon Green, LysoSensor Green, pHAb, fluorescein, FAM, rhodamine B derivatives, and SNARF.
- fluorescent proteins can be pH-dependent or pH-independent, which may be, but not limited to, green fluorescent proteins, yellow fluorescent proteins, or cyan fluorescent proteins.
- electroluminescent dyes may be fluolid dyes, such as Fluolid-Green, Fluolid-Orange, and Fluolid-Red.
- Chemiluminescent dyes may be, but not limited to, luminol, luciferin, or xanthene dyes.
- pH-dependent enzymes include horseradish peroxidase (HRP), glucose oxidase, and alkaline phosphatase.
- the signal produced by the signaling tag 20 may be an optical signal, an electronic signal, or a chemical signal.
- the optical signal may be in a form of, but not limited to, fluorescence, colorimetry, turbidometry, chemiluminescence, or electroluminescence.
- the chemical signal may be in a form of, but not limited to, radiation, or a pH change.
- FIG. 2 depicts a schematic diagram illustrating an interference of the presence of soluble binding partners of an analyte with the detection of an amount of the analyte in an assay.
- the assay may be a bridging ELISA assay.
- the analyte may be an ADA.
- the soluble binding partners may be drugs in the assay.
- binding partners 30 in the assay may bind to an analyte 32 , thereby forming a complex which may prevent the analyte 32 from binding to a capture molecule 34 or even to a detecting probe 36 .
- the formation of the complex may thus affect the accuracy of the detection of the amount of the analyte in the assay.
- FIG. 3 depicts a schematic diagram illustrating an acid pre-treatment step to dissociate analytes from soluble binding partners of the analytes in an assay.
- the assay may be a bridging ELISA assay.
- the analyte may be an ADA.
- the soluble binding partners may be drugs in the assay.
- soluble binding partners may bind to analytes, thereby forming complexes in the assay.
- the formation of such a complex occurs when a pH of a solution in the assay is 7, where soluble binding partners 52 bind to the analyte 50 .
- electrochemically active agents such as hydroquinone (HQ) 54
- the electrochemically active agents may either generate or consume hydrogen (H + ) ions in the solution through an electrochemical redox reaction (i.e. oxidation or reduction), which accordingly modifies the pH of the solution.
- the solution may include both HQ 54 and benzoquinone (BQ) (not shown). Controlling an electrical current applied to an electrode in contact with the solution may either induce an oxidization reaction of HQ 54 or a reduction reaction of BQ, thus either generating H + ions or consuming H + ions in the solution, respectively.
- BQ benzoquinone
- FIG. 3 illustrates a scenario where HQ 54 is oxidized under the influence of the electrical current (I) applied to the electrode 56 , generating BQ and H + ions in the solution.
- the oxidization reaction of HQ may thus modify the pH of the solution, especially an area in the solution that is close to the electrode 56 , from pH 7 to pH 4. Incubating the solution at pH 4 may allow the analyte 50 to be dissociated from the binding partners 52 .
- electrochemically active agents may also be utilized for electrochemically modulating a pH of a solution, such as quinone, catechol, aminophenol, hydrazine, naphthoquinone, derivatives thereof, or combinations thereof.
- Each of the electrochemically active agents may undergo an electrochemical redox reaction (i.e. oxidation or reduction) under the influence of an electrical current, which may either generate or consume H + ions in the solution for modulating the pH of the solution.
- FIG. 4 depicts a schematic diagram illustrating a first method embodiment for detecting an amount of an analyte in an assay.
- the assay may be a bridging ELISA assay.
- the analyte may be an ADA.
- an acid pre-treatment step may be performed to dissociate analytes from their soluble binding partners (e.g. drugs) bound to the analytes through electrochemically modulating a pH of a solution.
- the solution may include both HQ and BQ.
- an electrochemically active agent 72 such as HQ, may be oxidized.
- the oxidation of HQ generates H + ions in the solution, which induces a pH change of the solution from pH 7 to pH 4.
- Incubating the solution at pH 4 may allow the analyte 74 to be dissociated from the binding partners 76 and to bind to a capture molecule 78 .
- the capture molecule 78 may be attached to the electrode 70 via a linker 80 .
- the linker 80 is configured to immobilize the capture molecule 78 through adsorption, affinity, hybridization, or covalent bonding.
- an excess amount of detecting probes 82 may be added to the solution at pH 4.
- Each detecting probe 82 may have a signaling tag 84 attached thereto and configured to produce a signal at pH 4.
- the analyte 74 may bind to a detecting probe 82 at pH 4.
- a wash step may be performed to remove any unbound detecting probes 82 in the solution.
- the method may then measure the signals produced by the signaling tags 84 remained in the solution and calculate the amount of the analyte 74 in the assay based on the signals.
- FIG. 5 depicts a schematic diagram illustrating a second method embodiment for detecting an amount of an analyte in an assay.
- the assay may be a bridging ELISA assay.
- the analyte may be an ADA.
- an acid pre-treatment step may be performed to dissociate analytes from their soluble binding partners (e.g. drugs) bound to the analytes through electrochemically modulating a pH of a solution.
- the solution may include both HQ and BQ. Therefore, as shown in FIG. 5 , at pH 7, upon applying a first electrical current (I 1 ) to an electrode 100 in contact with a solution, an electrochemically active agent 102 , such as HQ, may be oxidized.
- I 1 first electrical current
- the oxidation of HQ generates H + ions in the solution, which induces a pH change of the solution from pH 7 to pH 4.
- Incubating the solution at pH 4 may allow the analyte 104 to be dissociated from the binding partners 106 .
- the pH of the solution may be further adjusted. As shown in FIG. 5 , upon applying a second electrical current (I 2 ) to the electrode 100 , BQ in the solution may be reduced. The reduction of BQ consumes H + ions in the solution, which induces a pH change of the solution from pH 4 to pH 7.
- I 2 second electrical current
- the solution may be transferred to an assay chamber, where the analyte 104 may bind to the capture molecule 108 .
- the capture molecule 108 may be attached to a solid substrate 110 in the assay chamber via a linker 112 .
- the linker 112 is configured to immobilize the capture molecule 108 through adsorption, affinity, hybridization, or covalent bonding.
- an excess amount of detecting probes 114 may be added to the solution at pH 7.
- Each detecting probe 114 may have a signaling tag 116 attached thereto and configured to produce a signal at pH 7.
- the analyte 104 may bind to the detecting probe 114 at pH 7.
- a wash step may be performed to remove any unbound detecting probes 114 in the solution. The method may then measure the signals produced by the signaling tags 116 remained in the solution and calculate the amount of the analyte 104 in the assay based on the signals.
- FIG. 6 depicts a schematic diagram illustrating a third method embodiment for detecting an amount of an analyte in an assay.
- the assay may be a bridging ELISA assay.
- the analyte may be an ADA.
- the method may be a one-pot immunoassay format for the detection of an amount of an analyte in the immunoassay.
- a pH of a solution in an assay chamber is 7, where an analyte 130 is bound by its binding partners 132 in the solution.
- the binding partners may be drugs in the assay.
- the assay chamber may also include detecting probes 134 which may have been added to the solution.
- Each detecting probe 134 may have a signaling tag 136 attached thereto and configured to produce a signal.
- an acid pre-treatment step may be performed to dissociate analytes from their soluble binding partners (e.g. drugs) bound to the analytes through electrochemically modulating a pH of a solution.
- the solution may include both HQ and BQ. Therefore, as shown in FIG. 6 , upon applying a first electrical current (I 1 ) to an electrode 138 in contact with the solution, an electrochemically active agent (not shown), such as HQ, may be oxidized. The oxidation of the electrochemically active agent generates H + ions in the solution, which modulates the pH of the solution from pH 7 to pH 4. Incubating the solution at pH 4 may allow the analyte 130 to be dissociated from the binding partners 132 .
- the pH of the solution may be further adjusted.
- applying a second electrical current (I 2 ) to the electrode 138 may reduce another electrochemically active agent (not shown), such as BQ, in the solution.
- the reduction reaction consumes H + ions in the solution, which induces a pH change of the solution from pH 4 to pH 7.
- the analyte 130 may bind to the capture molecule 140 .
- the capture molecule may be attached to the electrode 138 via a linker 142 .
- the linker 142 is configured to immobilize the capture molecule 140 through adsorption, affinity, hybridization, or covalent bonding. Further, the analyte 130 may bind to the detecting probe 134 in the solution at pH 7.
- the signaling tag 136 may be pH-independent, where the signaling tag 136 may produce the same signal when the pH of the solution is at either 4 or 7 .
- a wash step may be performed to remove any unbound detecting probes 134 in the solution. The method may then measure the signals produced by the signaling tags 136 remained in the solution and calculate the amount of the analyte 130 in the assay based on the signals.
- the signaling tag 136 may be pH-dependent, where the signaling tag 136 may produce a first signal at pH 4 and may produce a second signal at pH 7, the second signal being different from the first signal.
- an optimal pH for the signaling tag 136 to produce a signal is 7.
- the second signal produced at pH 7 may be stronger than the first signal produced at pH 4.
- a wash step may be performed to remove any unbound detecting probes 134 in the solution. The method may then measure the second signal produced by the signaling tags 136 remained in the solution and calculate the amount of the analyte 130 in the assay based on the second signal.
- FIG. 7 depicts a schematic diagram illustrating a fourth method embodiment for detecting an amount of an analyte in an assay.
- the assay may be a bridging ELISA assay.
- the analyte may be an ADA.
- the method may be a single-step immunoassay format for the detection of an amount of an analyte in the immunoassay.
- an assay chamber contains a solution of pH 4, where analytes 150 are not bound by their binding partners 152 in the solution.
- the binding partners 152 may be drugs in the assay chamber.
- the assay chamber may also include detecting probes 154 .
- Each detecting probe 154 may have a signaling tag 156 attached thereto.
- the signaling tag 156 may be pH-dependent in this method embodiment. As illustrated in FIG. 7 , the signaling tag 156 may not produce a signal (i.e. signal OFF) at pH 4.
- electrochemically active agents can subsequently modulate a pH of the solution in an automatic manner.
- the solution may include both HQ and BQ. Therefore, referring to FIG. 7 , by applying a first electrical current (I 1 ) to an electrode 158 in contact with a solution in the assay chamber, a first electrochemically active agent (not shown) may be reduced, thereby consuming H + ions in the solution.
- a first electrical current I 1
- a first electrochemically active agent not shown
- the I 1 applied to the electrode 158 only the solution near a surface of the electrode 158 may undergo a pH change, while the pH of other areas of the solution may not be changed. Specifically, as shown in FIG.
- the reduction reaction of the first electrochemically active agent may induce a pH change from pH 4 to pH 7 near the surface of the electrode 158 , Area I (i.e. below a modulation line 164 ), whereas other areas of the solution, Area II (i.e. above the modulation line 164 ), may remain at pH 4. Accordingly, in Area II, at pH 4, the signaling tags 156 may still not produce signals (i.e. signal OFF). On the other hand, in Area I, at pH 7, an analyte 150 may bind to a capture molecule 160 . The capture molecule 160 may be attached to the electrode 158 via a linker 162 .
- the linker 162 is configured to immobilize the capture molecule 160 through adsorption, affinity, hybridization, or covalent bonding.
- the analyte 150 may bind to a detecting probe 154 , and the signaling tag 156 attached to the detecting probe 154 may produce a first signal.
- an optimal pH for the analyte 150 to bind to the capture molecule 160 and to the detecting probe 154 may be 7.
- an optimal pH for the signaling tag 156 to produce a signal may be, for example, 8. Therefore, as shown in FIG. 7 , to obtain a stronger detecting signal produced by the signaling tag 156 , the method may further slightly adjust the pH of the solution from 7 to 8 by applying a second electrical current (I 2 ) to the electrode 158 .
- I 2 second electrical current
- the signaling tags 156 may still not produce signals (i.e. signal OFF).
- the analyte 150 may still bind to the capture molecule 160 and to the detecting probe 154 .
- the signaling tag 156 attached to the detecting probe 154 may produce a second signal. Since the signaling tag 156 is pH-dependent, and the optimal pH for the signaling tag 156 to produce a signal is 8, the second signal may be, therefore, stronger than the first signal produced at pH 7. As such, the amount of the analyte 150 in the assay chamber may be accurately calculated based on the second signal.
- FIG. 8 depicts a schematic diagram illustrating a fifth method embodiment for detecting an amount of an analyte in an assay.
- the assay may be a bridging ELISA assay.
- the analyte may be an ADA.
- the method may be a single-step immunoassay format for the detection of an amount of an analyte in the immunoassay.
- a pH of a solution in an assay chamber is 7, where analytes 170 are bound by their binding partners 172 in the solution.
- the binding partners 172 may be drugs in the assay chamber.
- the assay chamber may also include detecting probes 174 .
- Each detecting probe 174 may have a signaling tag 176 attached thereto.
- the signaling tag 176 may be pH-dependent in this method embodiment. As illustrated in FIG. 8 , the signaling tag 176 may not produce a signal (i.e. signal OFF) at pH 7.
- applying a first electrical current (I 1 ) to an electrode 178 in contact with the solution in the assay chamber may oxidize a first electrochemically active agent (not shown) in the solution, and the oxidization reaction of the first electrochemically active agent may induce a pH change of the solution.
- a first electrical current I 1
- the I 1 applied to the electrode 178 only the solution near a surface of the electrode 178 , Area III (i.e. below a modulation line 184 ), may undergo the pH change from pH 7 to pH 4, whereas the pH of other areas in the solution, Area IV (i.e. above the modulation line 184 ), may not be changed (i.e. remain at pH 7).
- the analyte 170 may still be bound by its binding partners 172 , and the signaling tag 176 may still not produce a signal.
- the analyte 170 may be dissociated from its binding partners 172 , and the signaling tag 176 may produce a signal (i.e. signal ON).
- a second electrical current (I 2 ) to the electrode 178 may trigger a second electrochemically active agent (not shown) in the solution to undergo a reduction reaction, thereby changing the pH of the solution at Area III back to pH 7.
- a second electrochemically active agent (not shown) in the solution to undergo a reduction reaction, thereby changing the pH of the solution at Area III back to pH 7.
- both areas of the solution, Area III and Area IV, are at pH 7, and an analyte 170 may bind to a capture molecule 180 in the assay chamber.
- the capture molecule 180 may be attached to the electrode 178 via a linker 182 .
- the linker 182 is configured to immobilize the capture molecule 160 through adsorption, affinity, hybridization, or covalent bonding.
- the signaling tag 176 may not produce a signal (i.e. signal OFF) even though the detecting probe 174 may bind to the analyte 170 .
- a third electrical current (I 3 ) may then be applied to the electrode 178 to initiate an oxidation reaction of a third electrochemically active agent (not shown) in the solution.
- the oxidation reaction may reduce the pH of the solution back to pH 4, especially the solution in Area III that is near to the surface of the electrode 178 .
- Incubating the solution at pH 4 can afford more analytes 170 to be dissociated from the binding partners 172 .
- applying a fourth electrical current (I 4 ) may once again bring the pH of the solution back to pH 7.
- Such a process of oxidation and reduction reactions of electrochemically active agents may repeat several times to maximize the number of analytes 170 that are not bound by binding partners 172 in the solution such that the analytes 170 are available to be detected by the detecting probes 174 .
- the signaling tag 176 is pH-dependent, and an optimal pH for the signaling tag 176 to produce a signal may be, for example, 5. Therefore, as shown in FIG. 8 , applying another electrical current (In) to the electrode 178 may further trigger another electrochemically active agent in the solution to undergo another oxidation reaction such that the pH of the solution, especially Area III, may further be modulated from 7 to 5. At pH 5, the analyte 170 may still bind to the capture molecule 180 and to the detecting probe 174 . In addition, the signaling tag 176 may produce a signal at pH 5. As such, the amount of the analyte 170 in the assay chamber may be accurately calculated based on the signal produced at pH 5.
- an optimal pH for the signaling tag 176 to produce a signal may be, for example, 5. Therefore, as shown in FIG. 8 , applying another electrical current (In) to the electrode 178 may further trigger another electrochemically active agent in the solution to undergo another oxidation reaction such that the pH of the solution, especially Area III, may
Abstract
Description
- The present disclosure relates to methods for detecting an amount of an analyte in a solution, for example, methods for detecting an amount of an analyte in an immunoassay.
- Suboptimal performance of protein assays is often due to sample complexity and non-specific interactions, especially for some immunogenicity assays and cytokine assays. For example, in an immunogenicity assay, drugs can bind to anti-drug antibodies (ADA), thereby forming drug-ADA complexes which can adversely affect an accurate quantification of the concentration of the ADA or the drug. In addition, cytokines and protein biomarkers often have native binding partners in blood and serum, and complexes can also be formed in an assay to affect an accurate detection of a target analyte. A pH treatment step can be performed to break up such complexes and other undesired interactions prior to assaying a sample. However, this step is often performed manually, which is not ideal for accurately measuring the concentration of a target analyte in the sample.
- According to one embodiment, a method for detecting an amount of an analyte in a solution is disclosed. The method may include adding an electrochemically active agent to the solution containing molecules other than the electrochemically active agent. The electrochemically active agent can generate or consume hydrogen (H+) ions in the solution through an electrochemical redox reaction. The method may also include applying an electrical current to a working electrode in contact with the solution containing the electrochemically active agent to initiate the electrochemical redox reaction to change a pH of the solution from a first pH value to a second pH value, where the second pH value may be different from the first pH value. The method may further include incubating the solution at the second pH value to allow the analyte to dissociate from the other molecules in the solution, where the incubating step may further include incubating the solution at the second pH value to allow the analyte to bind to a capture molecule connected to the working electrode via a linker. The method may also include reacting a detecting probe with the analyte to allow the detecting probe to bind to the analyte. The detecting probe may have a signaling tag attached thereto and configured to produce a signal at the second pH value. The method may further include collecting the signal to calculate the amount of the analyte in the solution.
- According to another embodiment, a method for detecting an amount of an analyte in a solution is disclosed. The method may include adding an electrochemically active agent to the solution containing molecules other than the electrochemically active agent. The electrochemically active agent can generate or consume hydrogen (H+) ions in the solution through an electrochemical redox reaction. The method may also include applying a first electrical current to a working electrode in contact with the solution containing the electrochemically active agent to initiate a first electrochemical redox reaction to change a pH of the solution from a first pH value to a second pH value, where the second pH value may be different from the first pH value. The method may further include incubating the solution at the second pH value to allow the analyte to dissociate from the other molecules in the solution. The method may also include applying a second electrical current to the working electrode to initiate a second electrochemical redox reaction to change the pH of the solution from the second pH value to a third pH value, where the third pH value may be different from the second pH value. The method may further include incubating the solution at the third pH value to allow the analyte to bind to a capture molecule connected to the working electrode via a linker. The method may also include reacting a detecting probe with the analyte to allow the detecting probe to bind to the analyte. The detecting probe may have a signaling tag attached thereto and configured to produce a signal at the third pH value. The method may further include collecting the signal to calculate the amount of the analyte in the solution.
- According to yet another embodiment, a method for detecting an amount of an analyte in a solution with a first pH value is disclosed. The method may include adding a detecting probe to the solution. The detecting probe may have a signaling tag attached thereto and configured not to produce a signal at the first pH value. The method may also include adding an electrochemically active agent to the solution containing molecules other than the electrochemically active agent and the detecting probe. The electrochemically active agent can generate or consume hydrogen (H+) ions in the solution through an electrochemical redox reaction. The method may further include applying a first electrical current to a working electrode in contact with the solution to initiate a first redox reaction to change a pH of the solution from the first pH value to a second pH value, where the second pH value may be different from the first pH value. The method may also include incubating the solution at the second pH value to allow the analyte to dissociate from the other molecules in the solution and to bind to a capture molecule connected to the working electrode via a linker and to the detecting probe. The signaling tag attached to the detecting probe may be configured to produce a first signal at the second pH value. The method may further include collecting the first signal to calculate a first amount of the analyte in the solution. The method may also include applying a second electrical current to the working electrode in contact with the solution to initiate a second redox reaction to change the pH of the solution from the second pH value to a third pH value, where the third pH value may be different from the second pH value. The method may further include incubating the solution at the third pH value, where the signaling tag may be configured to produce a second signal at the third pH value. The second signal may be stronger than the first signal. The method may also include collecting the second signal to calculate a second amount of the analyte in the solution, where the second amount may be higher than the first amount.
-
FIG. 1 depicts a schematic diagram of a method for detecting an amount of an analyte in an assay. -
FIG. 2 depicts a schematic diagram illustrating an interference of the presence of soluble binding partners of an analyte with the detection of an amount of the analyte in an assay. -
FIG. 3 depicts a schematic diagram illustrating an acid pre-treatment step to dissociate analytes from soluble binding partners of the analytes in an assay. -
FIG. 4 depicts a schematic diagram illustrating a first method embodiment for detecting an amount of an analyte in an assay. -
FIG. 5 depicts a schematic diagram illustrating a second method embodiment for detecting an amount of an analyte in an assay. -
FIG. 6 depicts a schematic diagram illustrating a third method embodiment for detecting an amount of an analyte in an assay. -
FIG. 7 depicts a schematic diagram illustrating a fourth method embodiment for detecting an amount of an analyte in an assay. -
FIG. 8 depicts a schematic diagram illustrating a fifth method embodiment for detecting an amount of an analyte in an assay. - Embodiments of the present disclosure are described herein. It is to be understood, however, that the disclosed embodiments are merely examples and other embodiments can take various and alternative forms. The figures are not necessarily to scale; some features could be exaggerated or minimized to show details of components. Therefore, specific structural and functional details disclosed herein are not to be interpreted as limiting, but merely as a representative basis for teaching one skilled in the art to variously employ the embodiments. As those of ordinary skill in the art will understand, various features illustrated and described with reference to any one of the figures can be combined with features illustrated in one or more other figures to produce embodiments that are not explicitly illustrated or described. The combinations of features illustrated provide representative embodiments for typical applications. Various combinations and modifications of the features consistent with the teachings of this disclosure, however, could be desired for applications or implementations.
- This present disclosure is not limited to the specific embodiments and methods described below, as specific components and/or conditions may, of course, vary. Furthermore, the terminology used herein is used only for the purpose of describing embodiments of the present disclosure and is not intended to be limiting in any way.
- As used in the specification and the appended claims, the singular form “a,” “an,” and “the” comprise plural referents unless the context clearly indicates otherwise. For example, reference to a component in the singular is intended to comprise a plurality of components.
- The description of a group or class of materials as suitable for a given purpose in connection with one or more embodiments implies that mixtures of any two or more of the members of the group or class are suitable. Description of constituents in chemical terms refers to the constituents at the time of addition to any combination specified in the description and does not necessarily preclude chemical interactions among constituents of the mixture once mixed.
- Except where expressly indicated, all numerical quantities in this description indicating dimensions or material properties are to be understood as modified by the word “about” in describing the broadest scope of the present disclosure.
- The first definition of an acronym or other abbreviation applies to all subsequent uses herein of the same abbreviation and applies mutatis mutandis to normal grammatical variations of the initially defined abbreviation. Unless expressly stated to the contrary, measurement of a property is determined by the same technique as previously or later referenced for the same property.
- Reference is being made in detail to compositions, embodiments, and methods of embodiments known to the inventors. The disclosed embodiments are merely exemplary of the present disclosure which may be embodied in various and alternative forms. Therefore, specific details disclosed herein are not to be interpreted as limiting, rather merely as representative bases for teaching one skilled in the art to variously employ the present disclosure.
- Biotherapeutics, such as proteins and monoclonal antibodies (mAbs), are growing fast on the pharmaceutical market. Currently, over 250 approved biotherapeutics are on the market, and more than 500 are under development. Biotherapeutics, compared to relatively small molecule drugs, are prone to the risk of immune responses. For example, an unwanted immunogenicity may lead to a production of anti-drug antibodies (ADAs), which can negatively impact drug levels in circulation and drug efficacy. In some cases, immune responses can be severe and life threatening. Therefore, to assess the risk of immune responses against biotherapeutics, pharmacokinetics (PK) and pharmacodynamics (PD) characterizations are necessary during pre-clinical development stages and clinical trials.
- To characterize PK and/or PD profiles for a biotherapeutic, it is important to accurately measure the concentration of ADAs, drugs, or both in an aqueous environment. However, high drug levels in the aqueous environment can adversely interfere with the detection of ADAs, especially in bridging assay formats. For example, in an immunogenicity assay, ADAs can form complexes with drugs in a sample solution, thereby preventing an accurate quantification of the concentration of the ADAs, the drugs, or both. Such an issue may be more common in multiple-dose studies, where drug concentrations remain high for a significant period of the studies.
- To overcome the issue, drug-tolerant assays have been developed. The drug-tolerant assays can measure the concentration of ADAs in the presence of drugs by adopting an acid treatment step. The acid treatment step can break up ADA-drug complexes and release ADAs and drugs to a sample solution. Some examples of the drug-tolerant assays include enzyme-linked immunosorbent assay (ELISA), affinity capture elution ELISA (ACE), biotin-drug extraction with acid dissociation (BEAD) assay, sample pretreatment bridging ELISA, acid dissociation radioimmunoassay, homogeneous mobility shift assay (HMSA), and precipitation and acid dissociation method.
- Besides ADAs, soluble drug targets may also present a challenge for immunoassays. When the ratio of drugs to drug targets is low, very few binding sites of the drugs are available to engage the drug targets that are immobilized in an immunoassay. However, when the ratio of drugs to drug targets are high, a reverse effect may be observed (i.e. very few binding sites of the drug targets are available to bind the drugs). Therefore, different ratios of drugs to drug targets in an immunoassay may also have an impact on the accuracy of measuring the PK and/or PD profiles for a biotherapeutic.
- To resolve the problem, an acid treatment step has been employed in performing an immunoassay. The acid treatment step may be conducted by modulating a pH of a sample solution, thereby dissociating drugs from drug targets and denaturing drug-binding epitopes on drug targets. The sample solution may then be neutralized and ready for analysis in an ELISA format. This method has been used for the detection of immunoglobulin G1 (IgG1) mAb in the presence of angiopoietin-2 (Ang2).
- Similarly, a sample may be subject to a mild acid treatment, followed by a direct analysis on the sample using a sandwich ELISA. This method does not denature drug-binding epitopes on drug targets, but it utilizes the ability of capture antibodies to bind to drugs at a specific pH value where the drugs and the drug targets remain dissociated (i.e. drugs are unbound to drug targets). This method has been applied to the detection of immunoglobulin G4 (IgG4) in the presence of a soluble circulating target.
- Further, an improved assay conducted in an acidic pH value has been utilized for the detection of interleukin 13 (IL-13) in human plasma and serum. Specifically, incubation of a sample at the acidic pH value can reduce non-specific binding and interference from IL-13 binding proteins. Examples of biomarkers known to have soluble binding partners in blood and serum are, but not limited to, interleukin 1 (IL-1), interleukin 18 (IL-18), insulin-like growth factor 1 (IGF-1), tumor necrosis factor-beta (TNF-β), and testosterone.
- To perform a bridging ELISA protocol, a sample solution may be diluted in acetic acid and then incubated for 1 hour. Thereafter, the solution may be mixed with a basic buffer (e.g. Tris pH 9.5) and then added to an assay plate which contains a surface-bound capture molecule (e.g. antigen). The solution may then be incubated for another 1 to 5 hours, followed by washing and signal amplification steps (e.g. using horseradish peroxidase, or alkaline phosphatase).
- In view of the foregoing, the acid treatment step introduced in each method is performed manually. Manual operations can unavoidably introduce human errors, causing a low reproducibility of an assay. Therefore, there is a need to detect an amount of an analyte, such as an ADA, in an immunoassay in a more efficient and accurate manner.
- In contrast to manually adjusting a pH of a sample solution, the pH of the sample solution may be modulated automatically. Methods of electrochemically modulating a pH of a sample solution, especially varying the pH of the sample solution near an electrode surface, have been disclosed in U.S. patent application Ser. Nos. 14/792,569 and 13/543,300, which are hereby incorporated by reference in their entirety. Generally, modulating pH electrochemically can give advantages toward performing an assay, including reducing the number of manual steps and reagents, shortening assay times, allowing multiplexing, and improving measurement accuracy. A system for electrochemically modulating a pH of a sample solution may include a working electrode and a counter electrode. The system may also include an electrochemically active agent, such as quinone, which may be added to the sample solution. The electrochemically active agent may undergo an electrochemical redox reaction (i.e. oxidation or reduction) under the influence of an electrical current. The electrochemical redox reaction of the electrochemically active agent may generate or consume hydrogen (H+) ions, causing a pH change in the sample solution. By controlling the electrical current applied to the working electrode, only the sample solution near a surface of the working electrode may undergo the pH change while the pH of other areas of the sample solution that are not near the surface of the working electrode may not be affected. In addition, the system may also include a reference electrode and a sensing electrode. The sensing electrode may actively measure the pH of the sample solution in real time. Signals generated from the sensing electrode may be transmitted to electronics and fed into a closed loop algorithm, which may be used to control the electrical current applied to the working electrode and configured to either change or maintain the pH in the sample solution. Such an automatic method of pH modulation may be applied to analyzing immunoassays and other bioassays which may involve biomarkers that have soluble binding partners.
- Aspects of the present disclosure are directed to methods for detecting an amount of an analyte in a solution using an electrochemical pH modulation technology. The solution may include soluble binding partners of the analyte, which may bind to analytes in the solution to form complexes. The soluble binding partners may be drugs in the solution. The solution may also include detecting probes configured to bind to the analytes in the solution for detecting the amount of the analyte in the solution. Each detecting probe may include a signaling tag attached thereto. In one embodiment, aspects of the present disclosure include an acid pre-treatment step where analytes, such as anti-drug antibodies (ADAs), may be dissociated from their binding partners, followed by binding to capture molecules and to detecting probes for detecting an amount of an analyte in a solution. In another embodiment, aspects of the present disclosure include an acid pre-treatment step where analytes, such as ADAs, may be dissociated from their binding partners, followed by electrochemically modulating (e.g. neutralizing) a pH of a solution to allow the analytes to bind to capture molecules and to detecting probes for detecting an amount of an analyte in the solution. In yet another embodiment, aspects of the present disclosure utilize detecting probes having pH-dependent signaling tags attached thereto for detecting an amount of an analyte, such as an ADA, in a solution, where a pH-dependent signaling tag may produce a first signal when the solution is at a first pH value, and may produce a second signal when the solution is at a second pH value different from the first pH value.
-
FIG. 1 depicts a schematic diagram of a method for detecting an amount of an analyte in an assay. The assay may be a bridging ELISA assay. The analyte may be an ADA. As shown inFIG. 1 , acapture molecule 10 is attached to a solid substrate 12 (e.g. an electrode) via alinker 14. Ananalyte 16 may bind to thecapture molecule 10. A detectingprobe 18 may be present in the assay and may include asignaling tag 20 attached thereto. As illustrated inFIG. 1 , the detectingprobe 18 may bind to theanalyte 16, and thesignaling tag 20 may produce a signal. Thereafter, the amount of theanalyte 16 in the assay may be calculated based on the signal. - The
linker 14 is configured to immobilize thecapture molecule 10 and to preserve the functionality thereof. Specifically, thelinker 14 may be a polymeric material configured to immobilize the capture molecule through adsorption. The polymeric material may be, but not limited to, polystyrene, polymethyl methacrylate (PMMA), polypropylene, cyclic olefin copolymer, agarose, dextran, or nitrocellulose. The linker may also be a peptide sequence or a protein configured to immobilize the capture molecule through affinity. The peptide sequence or the protein may be, but not limited to, streptavidin, protein A, or protein G, an aptamer, or a polyhistidine tag (His-Tag). In addition, the linker may be a polynucleic acid configured to immobilize the capture molecule through hybridization. Further, the linker may be an organic molecule for immobilizing the capture molecule through covalent bonding. The organic molecule may be, but not limited to, maleimide, succinimide, (trifluoromethyl)phenyldiaziridine, amine, hydrazide, boronic acid, iodoacetyl, epoxide, thiol, azide, or alkyne. - The
signaling tag 20 may be pH-dependent or pH-independent. Basically, a pH-dependent signaling tag may change its behavior as a function of a pH of a solution. For example, a pH-dependent signaling tag may produce a first signal at a first pH value and may produce a second signal at a second pH value, where the first and the second pH value are different. On the contrary, a pH-independent signaling tag may not change its behavior as a function of a pH of a solution, but rather produce a signal when it presents in a solution. - As to compositions, the
signaling tag 20 may be a fluorescent tag, a fluorescent dye, a fluorescent protein, an electroluminescent dye, a chemiluminescent dye, or an enzyme. - Specifically, fluorescent tags can be pH-dependent or pH-independent, which may be, but not limited to, organic dyes, quantum dots, lanthanide ions, or proteins. Fluorescent dyes may be, but not limited to, fluorescein, coumarin, rhodamin, cyanine, or derivatives thereof. Examples of commonly used fluorescent dyes include fluorescein isothiocyanate (FITC), tetramethylrhodamine isothiocyanate (TRITC), Alexa Fluor, Cy-3, Cy-5, and ATTO dyes. Examples of pH-dependent fluorescent dyes may include, but not limited to, pHrodo, Protonex, Oregon Green, LysoSensor Green, pHAb, fluorescein, FAM, rhodamine B derivatives, and SNARF. In addition, fluorescent proteins can be pH-dependent or pH-independent, which may be, but not limited to, green fluorescent proteins, yellow fluorescent proteins, or cyan fluorescent proteins. Further, electroluminescent dyes may be fluolid dyes, such as Fluolid-Green, Fluolid-Orange, and Fluolid-Red. Chemiluminescent dyes may be, but not limited to, luminol, luciferin, or xanthene dyes. Examples of pH-dependent enzymes include horseradish peroxidase (HRP), glucose oxidase, and alkaline phosphatase.
- Referring to
FIG. 1 , the signal produced by thesignaling tag 20 may be an optical signal, an electronic signal, or a chemical signal. Particularly, the optical signal may be in a form of, but not limited to, fluorescence, colorimetry, turbidometry, chemiluminescence, or electroluminescence. Further, the chemical signal may be in a form of, but not limited to, radiation, or a pH change. -
FIG. 2 depicts a schematic diagram illustrating an interference of the presence of soluble binding partners of an analyte with the detection of an amount of the analyte in an assay. The assay may be a bridging ELISA assay. The analyte may be an ADA. The soluble binding partners may be drugs in the assay. As illustrated inFIG. 2 , bindingpartners 30 in the assay may bind to ananalyte 32, thereby forming a complex which may prevent theanalyte 32 from binding to acapture molecule 34 or even to a detectingprobe 36. The formation of the complex may thus affect the accuracy of the detection of the amount of the analyte in the assay. -
FIG. 3 depicts a schematic diagram illustrating an acid pre-treatment step to dissociate analytes from soluble binding partners of the analytes in an assay. The assay may be a bridging ELISA assay. The analyte may be an ADA. The soluble binding partners may be drugs in the assay. As described inFIG. 2 , soluble binding partners may bind to analytes, thereby forming complexes in the assay. Similarly, as shown inFIG. 3 , the formation of such a complex occurs when a pH of a solution in the assay is 7, where solublebinding partners 52 bind to theanalyte 50. To dissociate theanalyte 50 from the bounded bindingpartners 52, electrochemically active agents, such as hydroquinone (HQ) 54, may be added into the solution. The electrochemically active agents may either generate or consume hydrogen (H+) ions in the solution through an electrochemical redox reaction (i.e. oxidation or reduction), which accordingly modifies the pH of the solution. - Referring to
FIG. 3 , the solution may include both HQ 54 and benzoquinone (BQ) (not shown). Controlling an electrical current applied to an electrode in contact with the solution may either induce an oxidization reaction of HQ 54 or a reduction reaction of BQ, thus either generating H+ ions or consuming H+ ions in the solution, respectively. -
FIG. 3 illustrates a scenario where HQ 54 is oxidized under the influence of the electrical current (I) applied to theelectrode 56, generating BQ and H+ ions in the solution. -
HQ→BQ+2H++2e − (1) - The oxidization reaction of HQ may thus modify the pH of the solution, especially an area in the solution that is close to the
electrode 56, frompH 7 topH 4. Incubating the solution atpH 4 may allow theanalyte 50 to be dissociated from the bindingpartners 52. - Other electrochemically active agents may also be utilized for electrochemically modulating a pH of a solution, such as quinone, catechol, aminophenol, hydrazine, naphthoquinone, derivatives thereof, or combinations thereof. Each of the electrochemically active agents may undergo an electrochemical redox reaction (i.e. oxidation or reduction) under the influence of an electrical current, which may either generate or consume H+ ions in the solution for modulating the pH of the solution.
-
FIG. 4 depicts a schematic diagram illustrating a first method embodiment for detecting an amount of an analyte in an assay. The assay may be a bridging ELISA assay. The analyte may be an ADA. As described inFIG. 3 , an acid pre-treatment step may be performed to dissociate analytes from their soluble binding partners (e.g. drugs) bound to the analytes through electrochemically modulating a pH of a solution. The solution may include both HQ and BQ. Similarly, as shown inFIG. 4 , upon applying an electrical current (I) to anelectrode 70 in contact with the solution, an electrochemicallyactive agent 72, such as HQ, may be oxidized. The oxidation of HQ generates H+ ions in the solution, which induces a pH change of the solution frompH 7 topH 4. Incubating the solution atpH 4 may allow theanalyte 74 to be dissociated from the bindingpartners 76 and to bind to acapture molecule 78. Thecapture molecule 78 may be attached to theelectrode 70 via alinker 80. Thelinker 80 is configured to immobilize thecapture molecule 78 through adsorption, affinity, hybridization, or covalent bonding. - To accurately measure the amount of the
analyte 74 in the assay, an excess amount of detectingprobes 82 may be added to the solution atpH 4. Each detectingprobe 82 may have a signaling tag 84 attached thereto and configured to produce a signal atpH 4. As shown inFIG. 4 , theanalyte 74 may bind to a detectingprobe 82 atpH 4. Upon the completion of binding atpH 4, a wash step may be performed to remove any unbound detectingprobes 82 in the solution. The method may then measure the signals produced by the signaling tags 84 remained in the solution and calculate the amount of theanalyte 74 in the assay based on the signals. -
FIG. 5 depicts a schematic diagram illustrating a second method embodiment for detecting an amount of an analyte in an assay. The assay may be a bridging ELISA assay. The analyte may be an ADA. As both described inFIGS. 3 and 4 , an acid pre-treatment step may be performed to dissociate analytes from their soluble binding partners (e.g. drugs) bound to the analytes through electrochemically modulating a pH of a solution. The solution may include both HQ and BQ. Therefore, as shown inFIG. 5 , atpH 7, upon applying a first electrical current (I1) to anelectrode 100 in contact with a solution, an electrochemicallyactive agent 102, such as HQ, may be oxidized. The oxidation of HQ generates H+ ions in the solution, which induces a pH change of the solution frompH 7 topH 4. Incubating the solution atpH 4 may allow theanalyte 104 to be dissociated from the bindingpartners 106. - To afford optimal bindings between the
analyte 104 and acapture molecule 108 in the assay, and between theanalyte 104 and a detectingprobe 110, the pH of the solution may be further adjusted. As shown inFIG. 5 , upon applying a second electrical current (I2) to theelectrode 100, BQ in the solution may be reduced. The reduction of BQ consumes H+ ions in the solution, which induces a pH change of the solution frompH 4 topH 7. -
BQ+2H++2e −→HQ (2) - Thereafter, the solution may be transferred to an assay chamber, where the
analyte 104 may bind to thecapture molecule 108. Thecapture molecule 108 may be attached to asolid substrate 110 in the assay chamber via alinker 112. Thelinker 112 is configured to immobilize thecapture molecule 108 through adsorption, affinity, hybridization, or covalent bonding. - To accurately measure the amount of the
analyte 104 in the assay, an excess amount of detectingprobes 114 may be added to the solution atpH 7. Each detectingprobe 114 may have a signaling tag 116 attached thereto and configured to produce a signal atpH 7. As shown inFIG. 5 , theanalyte 104 may bind to the detectingprobe 114 atpH 7. Upon the completion of binding atpH 7, a wash step may be performed to remove any unbound detectingprobes 114 in the solution. The method may then measure the signals produced by the signaling tags 116 remained in the solution and calculate the amount of theanalyte 104 in the assay based on the signals. -
FIG. 6 depicts a schematic diagram illustrating a third method embodiment for detecting an amount of an analyte in an assay. The assay may be a bridging ELISA assay. The analyte may be an ADA. The method may be a one-pot immunoassay format for the detection of an amount of an analyte in the immunoassay. As shown inFIG. 6 , a pH of a solution in an assay chamber is 7, where ananalyte 130 is bound by its bindingpartners 132 in the solution. The binding partners may be drugs in the assay. AtpH 7, the assay chamber may also include detectingprobes 134 which may have been added to the solution. Each detectingprobe 134 may have asignaling tag 136 attached thereto and configured to produce a signal. As discussed above, an acid pre-treatment step may be performed to dissociate analytes from their soluble binding partners (e.g. drugs) bound to the analytes through electrochemically modulating a pH of a solution. The solution may include both HQ and BQ. Therefore, as shown inFIG. 6 , upon applying a first electrical current (I1) to anelectrode 138 in contact with the solution, an electrochemically active agent (not shown), such as HQ, may be oxidized. The oxidation of the electrochemically active agent generates H+ ions in the solution, which modulates the pH of the solution frompH 7 topH 4. Incubating the solution atpH 4 may allow theanalyte 130 to be dissociated from the bindingpartners 132. - To achieve optimal bindings between the
analyte 130 and acapture molecule 140 in the assay, and between theanalyte 130 and a detectingprobe 134, the pH of the solution may be further adjusted. As shown inFIG. 6 , applying a second electrical current (I2) to theelectrode 138 may reduce another electrochemically active agent (not shown), such as BQ, in the solution. The reduction reaction consumes H+ ions in the solution, which induces a pH change of the solution frompH 4 topH 7. AtpH 7, theanalyte 130 may bind to thecapture molecule 140. The capture molecule may be attached to theelectrode 138 via alinker 142. Thelinker 142 is configured to immobilize thecapture molecule 140 through adsorption, affinity, hybridization, or covalent bonding. Further, theanalyte 130 may bind to the detectingprobe 134 in the solution atpH 7. - In one embodiment, the
signaling tag 136 may be pH-independent, where thesignaling tag 136 may produce the same signal when the pH of the solution is at either 4 or 7. In this case, upon the completion of binding atpH 7, a wash step may be performed to remove any unbound detectingprobes 134 in the solution. The method may then measure the signals produced by the signaling tags 136 remained in the solution and calculate the amount of theanalyte 130 in the assay based on the signals. - In another embodiment, the
signaling tag 136 may be pH-dependent, where thesignaling tag 136 may produce a first signal atpH 4 and may produce a second signal atpH 7, the second signal being different from the first signal. In this embodiment, an optimal pH for thesignaling tag 136 to produce a signal is 7. In other words, the second signal produced atpH 7 may be stronger than the first signal produced atpH 4. In this case, upon the completion of binding atpH 7, a wash step may be performed to remove any unbound detectingprobes 134 in the solution. The method may then measure the second signal produced by the signaling tags 136 remained in the solution and calculate the amount of theanalyte 130 in the assay based on the second signal. -
FIG. 7 depicts a schematic diagram illustrating a fourth method embodiment for detecting an amount of an analyte in an assay. The assay may be a bridging ELISA assay. The analyte may be an ADA. The method may be a single-step immunoassay format for the detection of an amount of an analyte in the immunoassay. As shown inFIG. 7 , an assay chamber contains a solution ofpH 4, whereanalytes 150 are not bound by their bindingpartners 152 in the solution. The bindingpartners 152 may be drugs in the assay chamber. The assay chamber may also include detectingprobes 154. Each detectingprobe 154 may have asignaling tag 156 attached thereto. Thesignaling tag 156 may be pH-dependent in this method embodiment. As illustrated inFIG. 7 , thesignaling tag 156 may not produce a signal (i.e. signal OFF) atpH 4. - As discussed above, under the influence of an electrical current applied to an electrode in contact with a solution, electrochemically active agents can subsequently modulate a pH of the solution in an automatic manner. The solution may include both HQ and BQ. Therefore, referring to
FIG. 7 , by applying a first electrical current (I1) to anelectrode 158 in contact with a solution in the assay chamber, a first electrochemically active agent (not shown) may be reduced, thereby consuming H+ ions in the solution. In this method embodiment, by controlling the I1 applied to theelectrode 158, only the solution near a surface of theelectrode 158 may undergo a pH change, while the pH of other areas of the solution may not be changed. Specifically, as shown inFIG. 7 , the reduction reaction of the first electrochemically active agent may induce a pH change frompH 4 topH 7 near the surface of theelectrode 158, Area I (i.e. below a modulation line 164), whereas other areas of the solution, Area II (i.e. above the modulation line 164), may remain atpH 4. Accordingly, in Area II, atpH 4, the signaling tags 156 may still not produce signals (i.e. signal OFF). On the other hand, in Area I, atpH 7, ananalyte 150 may bind to acapture molecule 160. Thecapture molecule 160 may be attached to theelectrode 158 via alinker 162. Thelinker 162 is configured to immobilize thecapture molecule 160 through adsorption, affinity, hybridization, or covalent bonding. In addition, in Area I, atpH 7, theanalyte 150 may bind to a detectingprobe 154, and thesignaling tag 156 attached to the detectingprobe 154 may produce a first signal. - In this method embodiment, an optimal pH for the
analyte 150 to bind to thecapture molecule 160 and to the detectingprobe 154 may be 7. However, an optimal pH for thesignaling tag 156 to produce a signal may be, for example, 8. Therefore, as shown inFIG. 7 , to obtain a stronger detecting signal produced by thesignaling tag 156, the method may further slightly adjust the pH of the solution from 7 to 8 by applying a second electrical current (I2) to theelectrode 158. Similarly, by controlling the I2 applied to theelectrode 158, only the solution near the surface of theelectrode 158, Area I, may undergo the pH change, whereas other areas of the solution, Area II, may remain atpH 4. Accordingly, in Area II, atpH 4, the signaling tags 156 may still not produce signals (i.e. signal OFF). On the other hand, in Area I, atpH 8, theanalyte 150 may still bind to thecapture molecule 160 and to the detectingprobe 154. In addition, in Area I, atpH 8, thesignaling tag 156 attached to the detectingprobe 154 may produce a second signal. Since thesignaling tag 156 is pH-dependent, and the optimal pH for thesignaling tag 156 to produce a signal is 8, the second signal may be, therefore, stronger than the first signal produced atpH 7. As such, the amount of theanalyte 150 in the assay chamber may be accurately calculated based on the second signal. -
FIG. 8 depicts a schematic diagram illustrating a fifth method embodiment for detecting an amount of an analyte in an assay. The assay may be a bridging ELISA assay. The analyte may be an ADA. The method may be a single-step immunoassay format for the detection of an amount of an analyte in the immunoassay. As shown inFIG. 8 , a pH of a solution in an assay chamber is 7, whereanalytes 170 are bound by their bindingpartners 172 in the solution. The bindingpartners 172 may be drugs in the assay chamber. AtpH 7, the assay chamber may also include detectingprobes 174. Each detectingprobe 174 may have asignaling tag 176 attached thereto. Thesignaling tag 176 may be pH-dependent in this method embodiment. As illustrated inFIG. 8 , thesignaling tag 176 may not produce a signal (i.e. signal OFF) atpH 7. - Similar to
FIG. 7 , inFIG. 8 , applying a first electrical current (I1) to anelectrode 178 in contact with the solution in the assay chamber may oxidize a first electrochemically active agent (not shown) in the solution, and the oxidization reaction of the first electrochemically active agent may induce a pH change of the solution. In addition, by controlling the I1 applied to theelectrode 178, only the solution near a surface of theelectrode 178, Area III (i.e. below a modulation line 184), may undergo the pH change frompH 7 topH 4, whereas the pH of other areas in the solution, Area IV (i.e. above the modulation line 184), may not be changed (i.e. remain at pH 7). Accordingly, in Area IV, atpH 7, theanalyte 170 may still be bound by its bindingpartners 172, and thesignaling tag 176 may still not produce a signal. On the other hand, in Area III, theanalyte 170 may be dissociated from its bindingpartners 172, and thesignaling tag 176 may produce a signal (i.e. signal ON). - Thereafter, applying a second electrical current (I2) to the
electrode 178 may trigger a second electrochemically active agent (not shown) in the solution to undergo a reduction reaction, thereby changing the pH of the solution at Area III back topH 7. At this stage, both areas of the solution, Area III and Area IV, are atpH 7, and ananalyte 170 may bind to acapture molecule 180 in the assay chamber. Thecapture molecule 180 may be attached to theelectrode 178 via alinker 182. Thelinker 182 is configured to immobilize thecapture molecule 160 through adsorption, affinity, hybridization, or covalent bonding. However, as shown inFIG. 8 , atpH 7, thesignaling tag 176 may not produce a signal (i.e. signal OFF) even though the detectingprobe 174 may bind to theanalyte 170. - To ensure as much as
analytes 170 in the solution to be dissociated from their bindingpartners 172, a third electrical current (I3) may then be applied to theelectrode 178 to initiate an oxidation reaction of a third electrochemically active agent (not shown) in the solution. The oxidation reaction may reduce the pH of the solution back topH 4, especially the solution in Area III that is near to the surface of theelectrode 178. Incubating the solution atpH 4 can affordmore analytes 170 to be dissociated from the bindingpartners 172. Thereafter, applying a fourth electrical current (I4) may once again bring the pH of the solution back topH 7. Such a process of oxidation and reduction reactions of electrochemically active agents may repeat several times to maximize the number ofanalytes 170 that are not bound by bindingpartners 172 in the solution such that theanalytes 170 are available to be detected by the detecting probes 174. - Referring to
FIG. 8 , thesignaling tag 176 is pH-dependent, and an optimal pH for thesignaling tag 176 to produce a signal may be, for example, 5. Therefore, as shown inFIG. 8 , applying another electrical current (In) to theelectrode 178 may further trigger another electrochemically active agent in the solution to undergo another oxidation reaction such that the pH of the solution, especially Area III, may further be modulated from 7 to 5. AtpH 5, theanalyte 170 may still bind to thecapture molecule 180 and to the detectingprobe 174. In addition, thesignaling tag 176 may produce a signal atpH 5. As such, the amount of theanalyte 170 in the assay chamber may be accurately calculated based on the signal produced atpH 5. - While exemplary embodiments are described above, it is not intended that these embodiments describe all possible forms encompassed by the claims. The words used in the specification are words of description rather than limitation, and it is understood that various changes can be made without departing from the spirit and scope of the disclosure. As previously described, the features of various embodiments can be combined to form further embodiments of the present disclosure that may not be explicitly described or illustrated. While various embodiments could have been described as providing advantages or being preferred over other embodiments or prior art implementations with respect to one or more desired characteristics, those of ordinary skill in the art recognize that one or more features or characteristics can be compromised to achieve desired overall system attributes, which depend on the specific application and implementation. These attributes can include, but are not limited to cost, strength, durability, life cycle cost, marketability, appearance, packaging, size, serviceability, weight, manufacturability, ease of assembly, etc. As such, to the extent any embodiments are described as less desirable than other embodiments or prior art implementations with respect to one or more characteristics, these embodiments are not outside the scope of the disclosure and can be desirable for particular applications.
Claims (20)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/881,489 US20210364506A1 (en) | 2020-05-22 | 2020-05-22 | Methods for detecting an amount of an analyte in a solution |
DE102021205179.0A DE102021205179A1 (en) | 2020-05-22 | 2021-05-20 | METHOD OF DETECTING THE AMOUNT OF ANALYTE IN A SOLUTION |
CN202110561989.3A CN113702452A (en) | 2020-05-22 | 2021-05-21 | Method for detecting the amount of an analyte in a solution |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/881,489 US20210364506A1 (en) | 2020-05-22 | 2020-05-22 | Methods for detecting an amount of an analyte in a solution |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210364506A1 true US20210364506A1 (en) | 2021-11-25 |
Family
ID=78408790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/881,489 Pending US20210364506A1 (en) | 2020-05-22 | 2020-05-22 | Methods for detecting an amount of an analyte in a solution |
Country Status (3)
Country | Link |
---|---|
US (1) | US20210364506A1 (en) |
CN (1) | CN113702452A (en) |
DE (1) | DE102021205179A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI502195B (en) * | 2009-03-10 | 2015-10-01 | Senova Systems Inc | Multi-phase analyte insensitive electrode for use in an electrochemical sensing device for measuring an analyte in a sample , electrochemical sensing device comprising the electrode and method of measuring an analyte in a sample using the electrochemical |
ES2410754T3 (en) * | 2010-05-25 | 2013-07-03 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Procedure for electrochemical detection of binding reactions |
US9810688B2 (en) * | 2013-03-15 | 2017-11-07 | Robert Bosch Gmbh | Smart glass slide for microarrays |
US9075041B2 (en) * | 2012-07-06 | 2015-07-07 | Robert Bosch Gmbh | Methods for generating pH/ionic concentration gradient near electrode surfaces for modulating biomolecular interactions |
KR102101987B1 (en) * | 2013-10-31 | 2020-04-20 | 리제너론 파마슈티칼스 인코포레이티드 | Competitive ligand binding assay for detecting neutralizing antibodies |
LU92920B1 (en) * | 2015-12-21 | 2017-07-13 | Luxembourg Inst Science & Tech List | Electrochemical reactor to control the pH in miniaturized dimensions |
-
2020
- 2020-05-22 US US16/881,489 patent/US20210364506A1/en active Pending
-
2021
- 2021-05-20 DE DE102021205179.0A patent/DE102021205179A1/en active Pending
- 2021-05-21 CN CN202110561989.3A patent/CN113702452A/en active Pending
Non-Patent Citations (3)
Title |
---|
ELISA - Wikipedia (Year: 2024) * |
Jones et al. "A substrate amplification system for enzyme-linked immunoassays. II. Demonstration of its applicability for measuring anti-DNA antibodies." J Immunol Methods. 1989 Mar 10;118(1):79-84 (Year: 1998) * |
Sigma "ALKALINE PHOSPHATASE — ASSAYS, MOLECULAR WEIGHT, SUBSTRATES, AND STRUCTURE", 2023, pp. 1-6 (Year: 2023) * |
Also Published As
Publication number | Publication date |
---|---|
DE102021205179A1 (en) | 2021-11-25 |
CN113702452A (en) | 2021-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cho et al. | Chemiluminometric enzyme-linked immunosorbent assays (ELISA)-on-a-chip biosensor based on cross-flow chromatography | |
CA2753598C (en) | Solution phase homogeneous assays | |
Lai et al. | Electrochemical stripping analysis of nanogold label-induced silver deposition for ultrasensitive multiplexed detection of tumor markers | |
US9040252B2 (en) | Method for increasing and regulating light emission from a chemiluminescent reaction | |
Zhang et al. | Enhanced ELISA using a handheld pH meter and enzyme-coated microparticles for the portable, sensitive detection of proteins | |
Park et al. | Development of a chemiluminescent immunosensor for chloramphenicol | |
CN108362687B (en) | Chemiluminescence enhancement solution, chemiluminescence substrate and application thereof | |
Ouyang et al. | Novel chemiluminescent immunochromatographic assay using a dual-readout signal probe for multiplexed detection of pesticide residues | |
CN102959397B (en) | Method for electrochemically detecting binding reactions | |
Liu et al. | Prostate-specific antigen detection by using a reusable amperometric immunosensor based on reversible binding and leasing of HRP-anti-PSA from phenylboronic acid modified electrode | |
Shi et al. | Signal amplification in capillary electrophoresis based chemiluminescent immunoassays by using an antibody–gold nanoparticle–DNAzyme assembly | |
Florentinus-Mefailoski et al. | Enzyme linked immuno mass spectrometric assay (ELIMSA) | |
Li et al. | Luminol, horseradish peroxidase and antibody ternary codified gold nanoparticles for a label-free homogenous chemiluminescent immunoassay | |
US9588123B2 (en) | Compositions and methods for in vitro diagnostic tests including zwitterionic solubilization reagent | |
Pereira et al. | Microfluidic immunosensor with gold nanoparticle platform for the determination of immunoglobulin G anti-Echinococcus granulosus antibodies | |
Watanabe et al. | The immune complex transfer enzyme immunoassay: Mechanism of improved sensitivity compared with conventional sandwich enzyme immunoassay | |
Zhao et al. | Multiple chemiluminescence immunoassay detection of the concentration ratio of glycosylated hemoglobin A1c to total hemoglobin in whole blood samples | |
Yu et al. | A gold nanoparticles growth-based immunoassay for detection of antibiotic residues | |
US20210364506A1 (en) | Methods for detecting an amount of an analyte in a solution | |
Yun-Xiang et al. | Application of a mimetic enzyme for the enzyme immunoassay for α-1-fetoprotein | |
Gupta et al. | Recent advances in biosensors for diagnosis of celiac disease: A review | |
Wang et al. | Protein functionalized titania particle as a nanocarrier in a multiple signal antibody amplification strategy for ultrasensitive chemiluminescent immunoassay | |
Chung et al. | Sequential analysis of multiple analytes using a surface plasmon resonance (SPR) biosensor | |
Tseng et al. | A simple, sensitive and compact electrochemical ELISA for estradiol based on chitosan deposited platinum wire microelectrodes | |
El-Maghrabey et al. | Development of quinone linked immunosorbent assay (QuLISA) based on using Folin’s reagent as a non-enzymatic tag: Application to analysis of food allergens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ROBERT BOSCH GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FOMINA, NADEZDA;JOHNSON, CHRISTOPHER;SHIN, YOUNG SHIK;AND OTHERS;SIGNING DATES FROM 20200508 TO 20200521;REEL/FRAME:052734/0710 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |